American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006.
about
Inflammatory bowel disease imaging: Current practice and future directionsAdalimumab treatment in Crohn's disease: an overview of long-term efficacy and safety in light of the EXTEND trialUse of the tumor necrosis factor-blockers for Crohn's diseaseGinsenoside metabolite compound K promotes recovery of dextran sulfate sodium-induced colitis and inhibits inflammatory responses by suppressing NF-κB activationShort-term study of infliximab treatment for Crohn's disease in China.Defining quality indicators for best-practice management of inflammatory bowel disease in Canada.Impact of pain on health-related quality of life in patients with inflammatory bowel diseaseRandomized controlled trial: moxibustion and acupuncture for the treatment of Crohn's disease.Moxibustion down-regulates colonic epithelial cell apoptosis and repairs tight junctions in rats with Crohn's diseaseL-arginine supplementation improves responses to injury and inflammation in dextran sulfate sodium colitisEfficacy and safety of adalimumab in Crohn's diseaseAppropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists.Utilization trends of anti-TNF agents and health outcomes in adults and children with inflammatory bowel diseases: a single-center experience.The apolipoprotein E-mimetic peptide COG112 inhibits NF-kappaB signaling, proinflammatory cytokine expression, and disease activity in murine models of colitis.Risk of infections associated with biological treatment in inflammatory bowel disease.Measuring patients' satisfaction with their anti-TNF treatment in severe Crohn's disease: scoring and psychometric validation of the Satisfaction for PAtients in Crohn's diseasE Questionnaire (SPACE-Q(©)).Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trialMRI in patients with inflammatory bowel diseaseAssessing patients' satisfaction with anti-TNFα treatment in Crohn's disease: qualitative steps of the development of a new questionnaire.Certolizumab pegol for the treatment of Crohn's disease.Managing refractory Crohn's disease: challenges and solutionsCancer and immunomodulators in inflammatory bowel diseases.Variation in treatment of patients with inflammatory bowel diseases at major referral centers in the United States.Berberine promotes recovery of colitis and inhibits inflammatory responses in colonic macrophages and epithelial cells in DSS-treated mice.Neuronal guidance molecule netrin-1 attenuates inflammatory cell trafficking during acute experimental colitisInhibition of Interleukin-10 Signaling Induces Microbiota-dependent Chronic Colitis in Apolipoprotein E Deficient Mice.Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's disease: correlation with SES-CD and clinical-biological markers.Multifactorial patterns of gene expression in colonic epithelial cells predict disease phenotypes in experimental colitis.Moxibustion regulates inflammatory mediators and colonic mucosal barrier in ulcerative colitis rats.The apolipoprotein E-mimetic peptide COG112 inhibits the inflammatory response to Citrobacter rodentium in colonic epithelial cells by preventing NF-kappaB activation.Netrin-1 regulates colon-kidney cross talk through suppression of IL-6 function in a mouse model of DSS-colitis.Prospective evaluation of MR enterography as the primary imaging modality for pediatric Crohn disease assessment.Maintenance of medically induced remission of Crohn's disease.Role of biologics and other therapies in stricturing Crohn's disease: what have we learnt so far?Controversies in the treatment of Crohn's disease: the case for an accelerated step-up treatment approachIs there a role for bowel rest in nutrition management of Crohn's disease?Fermented Pueraria Lobata extract ameliorates dextran sulfate sodium-induced colitis by reducing pro-inflammatory cytokines and recovering intestinal barrier function.CXCR2 knockout mice are protected against DSS-colitis-induced acute kidney injury and inflammation.Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies.Different brain responses to electro-acupuncture and moxibustion treatment in patients with Crohn's disease.
P2860
Q26774602-1257A15B-B874-428B-9009-FDA15C8C61FAQ26829488-47C0CFC6-1E85-469A-B456-998BBD9B61DAQ27030762-8B23DA41-2CD6-4B39-9D81-814F13F33114Q28539497-89A198AD-0739-499F-B37F-4CDE963D3EBBQ33394485-F116C14B-339C-4635-82C7-55F141EA6714Q33725615-CDD70E84-2F3E-49AF-963C-F1A2E727BF81Q33960394-DAE1BF17-C897-48F8-8D76-278242F61F4FQ34067969-5443B332-D5AD-4BE6-99FA-9BBB1C3CCDF1Q34102639-616F0A74-3592-49B1-9070-57B040F4455FQ34201063-1BFAB10E-C241-4020-9A09-B29718372AA9Q34408865-9364899C-356D-4927-B836-A548847ABCFCQ34476049-0BFFAD40-F17A-459A-B4A6-E18EFF8152BAQ34489872-340760BE-B059-4464-A80F-E0D333268253Q34537041-00F69F5C-BA84-4990-9B9D-E9600A8E3B60Q34552028-B3AC6A3E-984C-4C11-B766-58BD81CBE903Q34671143-5BE30F16-AA83-48BD-8CDA-3B47C81C9FC1Q34767921-9E420EDE-9A8C-481F-BAD9-8A9C99BA9F06Q34807714-9F273964-3E2E-4A94-93DF-7C28E7468341Q35186984-E0995236-F8F8-4BD0-A60B-10548282DF0CQ35276666-2962C7C2-445A-4A8B-BA2E-1C71261CBFAEQ35460367-FD2333D9-D3EA-45DA-B6CA-EA547423764BQ35534959-8BC34F8D-4E5A-4E5B-AA63-FB83AC676D2DQ35634719-0F4673CF-5817-4133-A0BE-CCC9E2D2B703Q35849974-54D4CFF1-54A6-4396-B4FE-6A0871B0D626Q35878812-775A301E-C0A1-4E81-98A9-DFCB64FE6399Q35927509-E9142B5D-8CA2-4C7F-BB7B-18D03B4B4D00Q36009845-45AC8496-833E-4D15-A26C-09FFE6496348Q36333341-063DAFC8-C670-4B4D-ACCA-6F6DA2D10515Q36621519-17CC5EA4-CBF6-47E0-A8B6-A462377EFDDDQ36711167-E29264C3-3175-49A4-B703-CEC83B39AD0DQ36836239-BF76F79D-5DA3-426C-B332-A674FF941CABQ37011345-A5D5F688-FFE7-43E8-988B-E3D40C169F7CQ37073410-408DE5DC-BFC5-402E-A345-602C1111321BQ37088847-DFD5DF77-FF89-406C-B531-D2D0CAE674A3Q37156633-8AF7D745-8779-4158-B78A-720E7C9823B9Q37205419-04D72769-9524-4353-8045-9D3FF9168A73Q37325113-BB08DA72-8BE5-44C5-9EB8-DF7DEEC40D5DQ37342116-242CCAAB-D21F-42B2-83CC-1BA08162C1E8Q37367325-4F872A0C-C947-4D18-8D60-5FFF1B29E558Q37421640-C242C550-6ABF-47C3-9C8D-4B11FD01C891
P2860
American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
American gastroenterological a ...... wel disease, June 21-23, 2006.
@en
type
label
American gastroenterological a ...... wel disease, June 21-23, 2006.
@en
prefLabel
American gastroenterological a ...... wel disease, June 21-23, 2006.
@en
P2093
P50
P921
P1433
P1476
American gastroenterological a ...... wel disease, June 21-23, 2006.
@en
P2093
Brian C Feagan
Bruce E Sands
Carol Regueiro
Lloyd Mayer
Michael A Kamm
Michael Clark
Richard N Fedorak
Severine Vermeire
Simon Travis
Stefan Schreiber
P304
P356
10.1053/J.GASTRO.2007.05.006
P407
P577
2007-07-01T00:00:00Z